Oppenheimer has reiterated an Outperform rating on ORIC Pharmaceuticals and kept a $15.00 price target following the company’s fourth-quarter and full-year 2025 reporting. The stock is trading at $11.71, reflecting a 16% gain over the past week and a 43% advance year-to-date, though InvestingPro analysis indicates the shares may be trading above a Fair Value estimate.
On the clinical front, Oppenheimer drew attention to data for rinzimetostat in metastatic castration-resistant prostate cancer. The firm reported a 55% PSA50 response rate, a 20% PSA90 response rate and 59% circulating tumor DNA clearance. Rinzimetostat has moved into a dose optimization phase ahead of a planned Phase 3 trial start scheduled in the first half of 2026. Oppenheimer noted that rinzimetostat may set itself apart within the PRC2 development class based on safety and pharmacokinetic characteristics, while flagging that Pfizer’s forthcoming MEVPRO-1 readout will be an important comparator for the class.
ORIC’s other clinical programs also received attention. Oppenheimer highlighted systemic activity and central nervous system control observed with enozertinib in exon 20 and PACC datasets. The company has selected a Phase 3 monotherapy dose for enozertinib and is advancing a combination program with subcutaneous amivantamab.
From a balance-sheet perspective, InvestingPro data show ORIC holds more cash than debt and reports a current ratio of 14.65, pointing to robust near-term liquidity as the company progresses multiple clinical programs. Management is scheduled to participate in a fireside chat at Oppenheimer’s Healthcare Conference on February 25 at 12:00 PM EST.
Capital markets activity has been active. ORIC filed a prospectus supplement to permit the offer and sale of up to $200 million of common stock through an at-the-market offering program. That filing follows an earlier prospectus under which ORIC raised approximately $139.7 million. The new shelf expansion increases the company’s optionality for equity funding as it prepares for upcoming registrational activity.
Several other brokerages have recently published views on ORIC. H.C. Wainwright reiterated a Buy rating, citing what it called a catalyst-rich 2026 for the company. Piper Sandler initiated coverage with an Overweight rating, calling out ORIC-944’s potential as a key combination partner in prostate cancer regimens. Wells Fargo raised its price target to $25.00 and maintained an Overweight rating, attributing the change to encouraging enozertinib data. ORIC itself reported that its lead candidates have delivered promising clinical signals, with ORIC-944 showing potential efficacy in metastatic castration-resistant prostate cancer and preparations underway to initiate a Phase 3 registrational trial for ORIC-944 in the first half of 2026.
Taken together, the clinical readouts, upcoming class-level data such as Pfizer’s MEVPRO-1, and the company’s expanded financing capacity frame the near-term outlook for ORIC. Investors and market participants will be watching pivotal study starts, regulatory sequencing and any future capital-raising moves as the programs advance toward registrational milestones.
Additional context
This report reflects published analyst ratings, company disclosures on trials and filings, and InvestingPro-derived liquidity metrics as noted above.